Person:
Spaulding, Caitlin

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Spaulding

First Name

Caitlin

Name

Spaulding, Caitlin

Filters

2017 - 20182

Settings

Author's Publications: search.filters.isAuthorOfPublication.a25976a6-b4be-422d-9ef1-bb1714a1cd0e

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Narrowing the spectrum: the new frontier of precision antimicrobials
    (BioMed Central, 2017) Paharik, Alexandra E.; Schreiber, Henry L.; Spaulding, Caitlin; Dodson, Karen W.; Hultgren, Scott J.
    Editorial summary Antibiotics have become the standard of care for bacterial infections. However, rising rates of antibiotic-resistant infections are outpacing the development of new antimicrobials. Broad-spectrum antibiotics also harm beneficial microbial communities inhabiting humans. To combat antibiotic resistance and protect these communities, new precision antimicrobials must be engineered to target specific pathogens.
  • Thumbnail Image
    Publication
    Precision antimicrobial therapeutics: the path of least resistance?
    (Nature Publishing Group UK, 2018) Spaulding, Caitlin; Klein, Roger D.; Schreiber, Henry L.; Janetka, James W.; Hultgren, Scott J.
    The emergence of drug-resistant pathogens has led to a decline in the efficacy of traditional antimicrobial therapy. The rise in resistance has been driven by widespread use, and in some cases misuse, of antibacterial agents in treating a variety of infections. A growing body of research has begun to elucidate the harmful effects of broad-spectrum antibiotic therapy on the beneficial host microbiota. To combat these threats, increasing effort is being directed toward the development of precision antimicrobial therapeutics that target key virulence determinants of specific pathogens while leaving the remainder of the host microbiota undisturbed. This includes the recent development of small molecules termed “mannosides” that specifically target uropathogenic E. coli (UPEC). Mannosides are glycomimetics of the natural mannosylated host receptor for type 1 pili, extracellular appendages that promotes UPEC colonization in the intestine. Type 1 pili are also critical for colonization and infection in the bladder. In both cases, mannosides act as molecular decoys which potently prevent bacteria from binding to host tissues. In mice, oral treatment with mannosides simultaneously clears active bladder infection and removes intestinal UPEC while leaving the gut microbiota structure relatively unchanged. Similar treatment strategies successfully target other pathogens, like adherent-invasive E. coli (AIEC), an organism associated with Crohn’s disease (CD), in mouse models. While not without its challenges, antibiotic-sparing therapeutic approaches hold great promise in a variety of disease systems, including UTI, CD, otitis media (OM), and others. In this perspective we highlight the benefits, progress, and roadblocks to the development of precision antimicrobial therapeutics.